Area of research
Genetics · Neurology
Research interest
Research interests include Glioma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Hedgehog Signaling Pathway Studies, and Cancer, Hypoxia, and Metabolism.
Data-Driven Feedback Identifies Focused Ultrasound Exposure Regimens for Improved Nanotheranostic Targeting of the Brain.
ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma
Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma
First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients
Data-driven feedback augments ultrasound nanotheranostics in brain tumors
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity with High-Density Progenitor Cell Regions Correlating with High-Risk Disease
DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines
DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines.
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
The LIN28B-let-7-PBK pathway is essential for group 3 medulloblastoma tumor growth and survival.
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics
LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study
STAT3 is required for Smo-dependent signaling and mediates Smo-targeted treatment resistance and tumorigenesis in Shh medulloblastoma.
Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles
Tumour immune landscape of paediatric high-grade gliomas
Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026)
Intellectual functioning among case‐matched cohorts of children treated with proton or photon radiation for standard‐risk medulloblastoma
Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo.
Microengineered human blood–brain barrier platform for understanding nanoparticle transport mechanisms
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes
Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma
Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference